Could FEF 25–75 levels or blood eosinophil counts predict the presence or absence of bronchial hyperreactivity?

Kurtulus Aksu, Ali Firincioglulari, Ezgi Erdem, Funda Aksu

Abstract:

BACKGROUND AND AIM: The relationship between bronchial hyperreactivity (BHR) and lung function parameters and blood eosinophilia in suspected asthmatics is not clear. This study aimed to investigate the relationship between FEF 25-75 values and blood eosinophilia levels and BHR in patients with asthma symptoms.

MATERIALS AND METHODS: Demographic and spirometric data and blood eosinophil counts were compared between patients with and without significant BHR. Receiver operating characteristic (ROC) curve analysis was performed to evaluate FEF25–75 and blood eosinophil count cutoff values to distinguish BHR in these patients.

RESULTS: According to the data of 894 patients, with BHR in 182 (20.4%), FEF25%–75% were significantly lower and blood eosinophil counts were significantly higher in patients with BHR. The best discriminatory values to assess the nonevident BHR were 64.5% for FEF25–75 (sensitivity: 94.2% and specificity: 18.7%) and 164/µL for blood eosinophil count (sensitivity: 59.6% and specificity 60.2%). The rate of nonevident BHR was significantly different between patients with FEF25–75 <65% and ≥65% (54.7% and 81.9%, respectively, P < 0.001). Although significant, the rates of nonevident BHR in patients with blood eosinophil counts below and above the cutoff (85.5% and 72.6%, respectively, P = 0.012) were not as different as the rates in patients with FEF25–75 values below and above the cutoff.

CONCLUSION: FEF25–75 is associated with BHR in patients with asthma symptoms. Nonevident BHR is more likely if FEF25–75 ≥65 in suspected asthmatics. However, blood eosinophil count is not helpful in predicting the absence of BHR in suspected asthmatics.

Keywords:
Asthma, bronchial challenge test, eosinophilia, spirometry

Introduction

Documentation of airflow limitation with variable airflow limitation is required for the diagnosis of asthma according to international guidelines. To document airflow limitation in patients with asthma symptoms, a low forced expiratory volume in 1 s/forced vital
capacity (FEV1/FVC) ratio (<0.75–0.80 in adults) must be confirmed in at least one clinical visit. Documentation of a positive bronchodilator reversibility test is the most commonly appraised parameter to confirm the excessive variability in lung function for the diagnosis of asthma.\textsuperscript{[1]} When no positive bronchodilator reversibility test is detected in patients with asthma symptoms, the bronchial provocation test is an alternative diagnostic method to document excessive variability in lung function.\textsuperscript{[11,12]} Asthma diagnosis may be verified in patients if provocative concentration of methacholine producing a fall in FEV1 of 20\% (PC\textsubscript{20}) values are <4 mg/ml.\textsuperscript{[13]}

With increasing awareness of the contribution of small airways in the pathogenesis of asthma, forced expiratory flow in 25\%–75\% of vital capacity (FEF25–75) measurements were suggested to be a more sensitive parameter compared to FEV1 for diagnosis and follow-up of asthmatics.\textsuperscript{[14-16]} Impaired FEF25–75 may suggest bronchial hyperreactivity (BHR) in people who describe asthma symptoms. However, the main problem is that no guidelines are provided for finding normal FEF25–75 values.\textsuperscript{[7]}

The eosinophilic inflammation is in part responsible for airway hyperreactivity. As for the increase in eosinophil counts and eosinophil activation markers in respiratory tract isolates, the increase in eosinophils in peripheral blood is also associated with asthmatic disease activity.\textsuperscript{[8-12]} Eosinophilic airway inflammation may also be present in asthmatic patients with normal lung function and clinically well-controlled asthma.\textsuperscript{[13]} Therefore, conventional assessments of airway obstruction may not be sensitive enough to reflect the extent of asthmatic activity.

This study was designed to evaluate the relationship between spirometric parameters, particularly FEF25–75 and blood eosinophil counts and BHR, in patients with asthma symptoms. More specifically, it was aimed to assess whether impairment of FEF25–75 and increased blood eosinophilia is related to a more severe BHR in suspected asthmatics with no apparent reversible airway obstruction in spirometric tests.

**Materials and Methods**

**Data collection**

A retrospective study was conducted to evaluate the data of patients who were examined for symptoms suggestive of asthma and underwent methacholine challenge test in an outpatient clinic of a tertiary chest diseases hospital between January and December 2017. Adult patients aged 18–80 years with complete spirometric data in the file information were included in the study. Demographic data, spirometric values, and blood eosinophil levels of the patients were obtained from the hospital files. PC\textsubscript{20} values below 4 mg/ml in methacholine challenge tests were considered as significant BHR.\textsuperscript{[9]}

**Outcome measures**

Demographic and spirometric data and peripheral blood eosinophil counts were compared between patients with and without significant BHR. The relationship between lung function parameters and peripheral blood eosinophil count and significant BHR was evaluated. Discriminative values of FEF25\%–75\% and eosinophil counts for nonevident BHR were assessed.

**Statistical analysis**

Continuous variables were expressed as mean ± standard deviation, and categorical variables were expressed as numbers (percentages). For comparisons, independent student’s t-test and Chi-square test were used for continuous and categorical variables, respectively. The relationship between the presence of BHR and continuous variables was evaluated by Spearman’s correlation coefficient. A receiver operating characteristic (ROC) curve analysis was performed to assess the ability of the FEF25\%–75\% and peripheral blood eosinophil count levels to determine the absence of BHR. All statistical tests were two sided, and \textit{P} < 0.05 was considered statistically significant. The analyses were performed using Statistical Package for the Social Sciences, IBM Corp., Armonk, NY, USA version 22.

**Standard protocol approvals**

The study was approved by the Ankara Keçiören Educational Research Hospital Clinical Research Ethics Committee (December 21, 2018/614).

**Results**

The present study included 894 adults with a median age of 44 years (range: 58 years) and the gender distribution of 581 females (65.0\%) and 313 males (35.0\%). Among the study population, 182 patients (20.4\%) had significant BHR. While age and body mass index of patients with and without significant BHR were not different significantly, the proportion of females was significantly higher among patients with significant BHR compared to those without significant BHR (\textit{P} = 0.002). Peripheral blood eosinophil counts were present in the file information of 258 patients. All spirometric values, including FEV1, FVC, and FEF25–75 values, were significantly lower in patients with significant BHR compared to those without significant BHR, and mean blood eosinophil counts were significantly higher [Table 1]. Evaluation of the relationship between lung functions and blood eosinophil counts and significant BHR revealed that FEF25–75 and FEF25\%–75\% values are weak to moderately related to
**Discussion**

Our study shows that spirometric values, including FEF25–75, are significantly lower in patients with symptoms suggestive of asthma if they have significant BHR in the bronchial challenge test. FEF25–75 values above 64.5% predicted the absence of significant BHR with a sensitivity of 94.2%. There was no significant BHR in 81.9% of cases with FEF25–75 ≥65%, while this rate was 54.7% in patients with FEF25–75 <65%. However, the specificity of having FEF25–75 values above 64.5% in predicting the absence of BHR was 18.7%. Therefore, patients with FEF25–75 values above 64.5% probably do not have BHR, while it is highly probable that BHR may also not be seen in individuals with FEF25–75 values below 64.5%. According to our data, blood eosinophil counts were significantly higher in patients with BHR. In contrast to FEF25–75, no meaningful relationship between peripheral blood eosinophil count and significant BHR was found. To evaluate the absence of significant BHR, the best distinguishing value of the eosinophil count, 164/µL, was found to be 59.6% sensitive and 60.2% specific. Therefore, it is thought that blood eosinophil count values will not be relevant in evaluating the absence of BHR.

Although asthma is a global health problem that affects all age groups with an increasing prevalence worldwide, there still is no indicator for its definitive diagnosis.[1] As small airways are more sensitive to inflammatory and remodeling process, FEF25–75 can provide valuable information in asthma.[14,15] In a real-world study, it was reported that a large percentage of asthmatic children had impaired FEF25–75 values.[8] It has also been suggested that FEF25–75 may be an early marker of airflow limitation associated with eosinophilic inflammation, and low FEF25–75 levels are predictive

---

**Table 1: Demographical and laboratory data of patients with and without significant bronchial hyperreactivity (n=894)**

<table>
<thead>
<tr>
<th></th>
<th>Patients with significant BHR (n=182)</th>
<th>Patients without significant BHR (n=712)</th>
<th>P</th>
</tr>
</thead>
<tbody>
<tr>
<td>Age (years)</td>
<td>44 (55)</td>
<td>44 (58)</td>
<td>0.970</td>
</tr>
<tr>
<td>Gender</td>
<td></td>
<td></td>
<td></td>
</tr>
<tr>
<td>Female, n (%)</td>
<td>136 (74.7)</td>
<td>445 (62.5)</td>
<td>0.002*</td>
</tr>
<tr>
<td>Body mass index (kg/m²)</td>
<td>28.08±5.52</td>
<td>28.08±5.56</td>
<td>0.092</td>
</tr>
<tr>
<td>Spirometric values</td>
<td></td>
<td></td>
<td></td>
</tr>
<tr>
<td>FEV1 (L)</td>
<td>2.69±0.81</td>
<td>2.98±0.78</td>
<td>&lt;0.001***</td>
</tr>
<tr>
<td>FEV1%</td>
<td>86.02±13.59</td>
<td>92.23±13.31</td>
<td>&lt;0.001***</td>
</tr>
<tr>
<td>FVC (L)</td>
<td>3.30±0.99</td>
<td>3.51±0.94</td>
<td>0.009*</td>
</tr>
<tr>
<td>FVC%</td>
<td>86.06±13.49</td>
<td>88.85±12.29</td>
<td>0.012**</td>
</tr>
<tr>
<td>FEV1/FVC</td>
<td>81.96±5.88</td>
<td>85.08±5.98</td>
<td>&lt;0.001***</td>
</tr>
<tr>
<td>FEF25-75 (L)</td>
<td>2.73±0.95</td>
<td>3.47±1.33</td>
<td>&lt;0.001***</td>
</tr>
<tr>
<td>FEF25%-75%</td>
<td>85.50±22.72</td>
<td>105.75±29.93</td>
<td>&lt;0.001***</td>
</tr>
<tr>
<td>Blood eosinophil count (µL)†</td>
<td>304.4±401.6</td>
<td>182.2±165.2</td>
<td>0.001**</td>
</tr>
</tbody>
</table>

†Blood eosinophil count is studied in 258 patients, P significant at levels of *<0.01, **P<0.05, ***P<0.001. Data are expressed as mean±SD. BHR: Bronchial hyperreactivity, FEV1: Forced expiratory volume in 1 s, FVC: Forced vital capacity, FEF25%-75%: Forced expiratory flow at 25%-75% of the FVC, SD: Standard deviation. Independent student’s t-test, Chi-square test

**Table 2: Relationship between lung function parameters and significant bronchial hyperreactivity**

<table>
<thead>
<tr>
<th></th>
<th>R</th>
<th>P</th>
</tr>
</thead>
<tbody>
<tr>
<td>FEF25-75</td>
<td>0.269*</td>
<td>&lt;0.001</td>
</tr>
<tr>
<td>FEF25%-75%</td>
<td>0.286*</td>
<td>&lt;0.001</td>
</tr>
<tr>
<td>FEV1</td>
<td>0.159</td>
<td>&lt;0.001</td>
</tr>
<tr>
<td>FEV1%</td>
<td>0.179</td>
<td>&lt;0.001</td>
</tr>
<tr>
<td>FVC</td>
<td>0.094</td>
<td>0.005</td>
</tr>
<tr>
<td>FVC%</td>
<td>0.077</td>
<td>0.021</td>
</tr>
<tr>
<td>FEV1/FVC</td>
<td>0.223</td>
<td>&lt;0.001</td>
</tr>
<tr>
<td>Blood eosinophil count (µL)†</td>
<td>-0.150</td>
<td>0.016</td>
</tr>
</tbody>
</table>

*Weak−moderate correlation. FEV1: Forced expiratory volume in 1 s, FVC: Forced vital capacity, FEF25%-75%: Forced expiratory flow at 25%-75% of the FVC

significant BHR [Table 2]. ROC curves were analyzed to determine the optimal discrimination threshold values of FEF25–75 and blood eosinophils that rule out significant BHR. To assess the absence of significant BHR, the best discriminatory values were 64.5% for FEF25–75 (sensitivity: 94.2% and specificity: 18.7%) and 164/µL for eosinophil count (sensitivity: 59.6% and specificity: 60.2%) [Figure 1]. Using these cutoffs, the rates of cases with significant hyperreactivity in cases with FEF25–75 values below and above 65% and blood eosinophil counts below or above 164/µL were compared. While the rate of not having significant BHR was 54.7% in patients with FEF25–75 value <65%, this rate was 81.9% for cases with FEF25–75 value ≥65% (P < 0.001). The proportion of patients without significant BHR was also significantly different between patients with blood eosinophil counts ≤164/µL and >164/µL (85.5% and 72.6%, respectively, P = 0.012) [Table 3]. However, the difference between the rate of nonevident BHR in patients with blood eosinophil counts 164/µL and >164/µL was not as different as the rates found in patients with FEF25–75 values <65% and ≥65%.

---

**Aksu, et al.: FEF25–75, eosinophilia, and bronchial hyperreactivity**
for newly diagnosed asthma when conventional spirometry parameters are normal.\textsuperscript{[7,16]} Studies have been conducted on whether impaired FEF25–75 values can be used in the early diagnosis of asthma, as it reflects small-airway obstruction. It was reported that FEF25\%-75\% predicted was well correlated with bronchodilator responsiveness in asthmatic children with normal FEV1 and that FEF25\%-75\% may be clinically relevant in predicting reversible airflow obstruction.\textsuperscript{[17]} Two previous reports suggested that FEF25\%-75\% could potentially be a predictor of BHR. Patients with a positive methacholine challenge test were reported to have significantly lower FEF25\%-75\% compared to those with negative test results, and a low FEF25–75 could potentially predict BHR.\textsuperscript{[7,16]} In the study conducted by Raji \textit{et al.}, to determine the relationship between baseline FEF25–75 and BHR, a FEF25–75 cutoff value was not found to distinguish patients with and without hyperreactivity.\textsuperscript{[7]} In our study, patients with FEF25–75 ≥65\% had significantly higher rates of cases without significant BHR than those with FEF25–75 <65\%. Although the threshold value of FEF25–75 with high sensitivity and specificity could not be found in this study, the sensitivity of FEF25–75 values above 64.5\% indicating the absence of significant BHR was found to be 94.2\%. On the other hand, due to the low specificity of this threshold value, it was determined that FEF25–75 values below 64.5\% could not indicate the presence of BHR. In a multicenter study, investigating whether the use of FEF25\%-75\% and FEF75\% in spirometric examination adds more information than the FEV1, FVC, and FEV1/FVC ratio, it was concluded that it did not provide any superiority in clinical decision-making.\textsuperscript{[18]}

Eosinophilia is another parameter that reflects asthmatic activity.\textsuperscript{[10‑12]} However, the relationship between blood eosinophilia and BHR is not fully enlightened. In 2000, Gibson \textit{et al.} have reported that airway responsiveness is associated with the severity of airway inflammation in asthmatics.\textsuperscript{[19]} Furthermore, a strong association was reported between peripheral eosinophilia and airway hyperresponsiveness assessed by methacholine challenge test.\textsuperscript{[20]} In our study, mean blood eosinophil counts were significantly higher in patients with significant BHR compared to those without significant BHR. However, the threshold value of the blood eosinophil count to indicate the absence of significant BHR, calculated as 164/\textmu L by ROC analysis, had a sensitivity of only 59.6\% and a specificity of only 60.2\%. Therefore, no cutoff value of the blood eosinophil count was determined to be relevant in predicting BHR in patients with suspected asthma.
The major limitation of the present study is the lack of long-term follow-up of patients to assess the development of overt asthma and the course of patients’ asthma-related symptoms.

**Conclusion**

The present study demonstrates that FEF25–75 is associated with BHR in patients with asthma symptoms. It is more likely that BHR is not present in suspected asthmatics if FEF25–75 levels are ≥65. A FEF25–75 value above 65% in spirometric examination performed in patients with suspected asthma can rule out asthma, however with a low specificity.

**Acknowledgments**

The study was presented in Lung Health and Intensive Care Society, UASK 2019 Congress, Antalya, Turkey. Authors thank to Şefik Gökdemir for his technical support.

**Financial support and sponsorship**

Nil.

**Conflicts of interest**

There are no conflicts of interest.

**References**